You are currently browsing the archives for 22 September 2015.
Displaying 1 - 2 of 2 entries.

Sensitivity measures the proportion of actual positive as such correctly identified as such.

98 % had a positive predictive value , the. The proportion of patients with positive test results who are correctly diagnosed 82 % had a negative predictive value , the. Proportion of patients with negative test results who are correctly diagnosed Imaging classifications were also accurate for multiple system atrophy and progressive supranuclear palsy . Eidelberg Eidelberg commented: The excellent specificity and PPV of the imaging classification does not this test for diagnostic use as a screening tool.

The article is the work of Dr. David Eidelberg, Center for Neurosciences, The Feinstein Institute for Medical Research, Manhasset, and colleagues.. They all had Online First and in the February issue of The Lancet Neurology reported that brain scans using positron emission tomography with high accuracy the form of Parkinson’s can be a patient to identify brain scans Early diagnosis of the various forms Parkinson Give. Such early diagnosis is important to ensure that patients get the the correct treatment and do not receive ineffective treatments due to misdiagnosis.

In contrast to established anti-cancer agents

In contrast to established anti-cancer agents, BI 6727 works by selectively blocking a part the cell make-up for cell division for cell division. BI 6727 is one of a series of compounds developed by Boehringer Ingelheim in this area. Showed the activity of the polo-like kinase 1 , which is highly expressed in proliferating cells, and most tumors, BI 6727 effectively interferes with cell division and cell death induced thereby . Inhibition of cancer growth Due to its unique mechanism of typical side effects of established anti-mitotic agents such as neuropathy have not occurred induced. According to Professor Patrick Sch ffski, head of the Department of Medical Oncology at the University Hospital of Leuven, Belgium, Chairman of the Scientific Committee of the Congress, Secretary General of the EORTC and lead investigator of the study, the results indicate an exciting scientific advances. Compelling new science in areas such as cell-cycle kinase inhibition brings us part one step closer to a better understanding of the various ways in the growth and spread of tumors and will hopefully to to better treatments for the armory against this deadly disease said Professor Sch? Results to date for BI 6727 have shown safe safe in patients with advanced solid tumors and that it given potential anti-tumor activity of this agent certainly warrants further investigation, he added.

In the study, which assessed the maximum tolerated dose, overall safety, pharmacokinetics and preliminary efficacy of BI 6727, a total of 50 patients were treated at doses 12-450 mg. Results were encouraging, 32 percent of patients had stable disease and two patients with advanced bladder cancer and ovarian cancer were confirmed responses, the standard both before other failed and experimental treatments. The clear anti-tumor activity can be detected, not usually a Phase a Phase I study, showing the importance of these findings. Moreover, BI 6727 observed found well tolerated without serious adverse events.